Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153501 | 0.88 | ALDH1A1 (0.43) | ALDH1A1MAPK1L3MBTL1HCAR2SLC6A2 | |
| SCHEMBL6154936 | 0.85 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1HCAR2SLC6A2 | |
| SCHEMBL6153580 | 0.81 | ABCB1 (0.51) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL6330533 | 0.81 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1HCAR2SLC6A2 | |
| SCHEMBL5793033 | 0.80 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1HCAR2SLC6A2 | |
| SCHEMBL6153498 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1HCAR2SLC6A2 | |
| SCHEMBL6154481 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL6156217 | 0.80 | TSHR (0.55) | ALDH1A1MAPK1L3MBTL1HCAR2SLC6A2 | |
| SCHEMBL6154133 | 0.78 | MEN1 (0.50) | ALDH1A1MAPK1L3MBTL1KMT2ALMNA | |
| SCHEMBL6156588 | 0.78 | ALDH1A1 (0.47) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119341-A1 | 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these | UBE INDUSTRIES, LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1500642-A1 | 3-SUBSTITUTED OXYGLUTARIC DIESTER COMPOUND, OPTICALLY ACTIVE 3-SUBSTITUTED OXYGLUTARIC MONOESTER COMPOUND, AND PROCESSES FOR PRODUCING THESE | Ube Industries, Ltd. (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119341-A1 | 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these | OGDH, GLUL, ADSL | ALDH1A1 434/4885MAPK1 3475/4885L3MBTL1 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.